Innovent Biologics (01801): Sintilimab ZYBRIVO receives positive CHMP opinion recommending approval for first-line treatment of non-squamous non-small cell lung cancer

date
16/11/2026
Zhitong Finance APP News, Innovent Biologics (01801) announced that sintilimab (European trade name: Zybrivo) has received the first positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). The CHMP recommends the approval of the marketing authorization of sintilimab in combination with chemotherapy for the treatment of adult patients with advanced non-squamous non-small cell lung cancer (NSCLC). If approved by the European Commission, Zybrivo will expand first-line treatment options for lung cancer patients in Europe. Sintilimab is an immunotherapy drug and a fully human immunoglobulin G4 (IgG4) monoclonal antibody that can bind to programmed cell death protein 1 (PD-1).